0
0
59 words
0
Comments
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. | The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focu…
You are the first to view
https://www.fiercepharma.com/pharma/girding-against-keytruda-cliff-merck-splits-oncology-standalone-business-unit
Create an account or login to join the discussion